Palvella Therapeutics Reports $11.3 Million Net Loss in Latest Quarter

Palvella Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $11.3 million for the third quarter, compared to a loss of $6.8 million in the same period last year, marking an increase of 67.5%. For the nine months ended September 30, 2025, the net loss reached $29.0 million, up from $14.1 million in the prior year. Total operating expenses for the quarter were $10.2 million, a substantial increase from $5.1 million in the previous year, driven primarily by heightened research and development costs associated with ongoing clinical trials.

The company’s research and development expenses surged to $6.5 million for the third quarter, up from $3.2 million in the same period last year, reflecting increased investment in the clinical development of its lead product candidate, QTORIN rapamycin. General and administrative expenses also rose significantly, totaling $3.6 million for the quarter compared to $1.9 million in the prior year, largely due to increased personnel costs and professional services related to operating as a public company following the merger with Legacy Palvella.

Palvella's operational metrics indicate a focus on advancing its clinical programs. The company successfully completed enrollment in its Phase 3 SELVA trial for microcystic lymphatic malformations with 51 subjects and in its Phase 2 TOIVA trial for cutaneous venous malformations with 16 subjects. The company also announced plans to expand its QTORIN rapamycin development program into clinically significant angiokeratomas, a rare skin condition. These strategic developments are part of Palvella's broader goal to address unmet medical needs in rare skin diseases.

As of September 30, 2025, Palvella reported cash and cash equivalents of $63.6 million, down from $83.6 million at the end of 2024. The decrease in cash is attributed to net cash used in operating activities of $20.1 million during the nine months ended September 30, 2025. The company anticipates that its existing cash will be sufficient to fund operations into the second half of 2027, although it may need to raise additional capital to support ongoing clinical trials and potential commercialization efforts.

Looking ahead, Palvella remains focused on advancing its product candidates through clinical trials and regulatory submissions. The company does not expect to generate commercial revenue in the near term and is actively seeking additional financing to support its operations and development programs. The successful completion of its clinical trials and subsequent regulatory approvals will be critical for the company's future financial performance and market position.